Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Novartis Sheds RNAi Portfolio
by Lisa M. Jarvis
March 16, 2015
| A version of this story appeared in
Volume 93, Issue 11
RNAi-based drug developer Arrowhead Research will pay Novartis $10 million in cash and $25 million in stock to acquire its RNAi portfolio. The deal includes intellectual property related to RNAi therapeutics and three preclinical drug candidates. Novartis built its RNAi portfolio, which includes the intellectual property related to 30 drug targets, through a five-year pact with another RNAi drug developer, Alnylam. During the course of that collaboration, which ended in 2010, Novartis paid Alnylam $125 million in R&D funding.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter